Insider trade

Director sold ~$588K of JAZZ shares in the open market

Traded Mar 3, 2026 · Filed Mar 5, 2026

Why it stands out

A board member of Jazz Pharmaceuticals sold $588K of Jazz Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$587,843

Shares × reported transaction price

Timing vs results

7 days after results of Feb 24, 2026, 63 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−1.8%	−2.2%	+0.4%
30 days	+1.8%	−3.3%	+5.0%
90 days	+25.8%	+10.7%	+15.1%
180 days	+32.7%	+11.8%	+20.9%

Past results only. Not a forecast.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $185.500 to $186.4207. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Scheduled in advance6mo ago

Scheduled in advance6mo ago

Scheduled in advance6mo ago